3. Torcetrapib
It is most important to increase levels of HDL cholesterol it is cardioprotective. Inhibition of cholesteryl ester transfer protein (CETP) appears to be a new and most useful strategy to raise HDL cholesterol levels. Brousseau et al. conducted a small study of 19 individuals with HDL cholesterol levels <40 mg/dl (1 mmol/L). CETP inhibi¬tion by torcetrapib administered concomitantly with ator-vastatin resulted in a 61 and 46% increase in HDL levels in the atorvastatin and non-atorvastatin cohorts, respec¬tively. The 120-mg, twice daily dose of this investigational agent increased HDL cholesterol by 106%. Most diabetic patients have HDL levels less than 35 mg/dl (0.9 mmol/L); thus, it is expected that CETP inhibition would be life-saving. (see the chapters Cholesterol and Dyslipidemia.)

Страницы: 1 | 2